Astellas Completes Acquisition of Audentes Therapeutics

News
2020
2019
Archive

December 19, 2019

IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
December 18, 2019

Pear Therapeutics Announces First Patient Dosed in Part II of Pear-006 Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis
December 17, 2019

TMRW Life Sciences Raises $25 Million in Series B Funding Led by 5AM Ventures
December 17, 2019

Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU
December 16, 2019

Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care
December 13, 2019

scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX® and Highlights Corporate Objectives
December 9, 2019

Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting
December 9, 2019

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH)
December 9, 2019

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an “Off-The-Shelf” Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
December 5, 2019

Portal Announces 2nd Major Pharma Partnership with LEO Pharma